Search - tctmd.com

Displaying 201 - 220 of 855

Sort: Relevancy | Date

Should Conduction-System Pacing Be Top Choice for CRT?

News Conference News EHRA 2024

Should Conduction-System Pacing Be Top Choice for CRT?

April 15, 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

April 15, 2024

Ultralow-Temperature Cryoablation Promising for Monomorphic VT

News Conference News EHRA 2024

Ultralow-Temperature Cryoablation Promising for Monomorphic VT

April 12, 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

April 06, 2024

Main Results From The Step-hfpef Dm Trial

Presentation ACC 2024

Main Results From The Step-hfpef Dm Trial

Presenter: Mikhail Kosiborod

April 06, 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

April 06, 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

News Conference News ACC 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

Michael O'Riordan

April 06, 2024

TCTMD’s Top 10 Most Popular Stories for March 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2024

April 03, 2024

Evoque and Patisiran: A Tale of Two Regulatory Journeys

News Opinion Off Script

Evoque and Patisiran: A Tale of Two Regulatory Journeys

Sanjay Kaul, MD

March 29, 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

Biologic Winrevair Wins FDA Approval for Treatment of PAH

News Daily News

Biologic Winrevair Wins FDA Approval for Treatment of PAH

March 27, 2024

ICD Benefits Hold Up for Modern-day Primary Prevention, but Questions Remain

News Daily News

ICD Benefits Hold Up for Modern-day Primary Prevention, but Questions Remain

March 25, 2024

ACC Updates HFrEF Decision Pathway, Reinforcing the Four Pillars of Therapy

News Daily News

ACC Updates HFrEF Decision Pathway, Reinforcing the Four Pillars of Therapy

March 11, 2024

Small Study Hints at Potential for HF Bone Marrow Cell Therapy: CardiAMP-HF

News Conference News THT 2024

Small Study Hints at Potential for HF Bone Marrow Cell Therapy: CardiAMP-HF

Michael O'Riordan

March 08, 2024

How Meaningful Are Heart Failure Hospitalizations in Today’s RCTs?

News Daily News

How Meaningful Are Heart Failure Hospitalizations in Today’s RCTs?

March 07, 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

News Conference News THT 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Michael O'Riordan

March 07, 2024

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

News Conference News THT 2024

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

Michael O'Riordan

March 06, 2024

Semaglutide Winning Streak Continues in CKD With FLOW

News Daily News

Semaglutide Winning Streak Continues in CKD With FLOW

March 06, 2024

Impact Of Rapid Up-Titration of Guideline-Directed Medical Therapies On Quality of Life: Insights From The STRONG-HF Trial

Presentation THT 2024

Impact Of Rapid Up-Titration of Guideline-Directed Medical Therapies On Quality of Life: Insights From The STRONG-HF Trial

Presenter: Kamile Cerlinskaite-Bajore

March 06, 2024

AI Assisted Identification of Super responders for Ultrafiltration can Reduce 90-Day Readmission Rates: Evidence from AVOID-HF Trial

Presentation THT 2024

AI Assisted Identification of Super responders for Ultrafiltration can Reduce 90-Day Readmission Rates: Evidence from AVOID-HF Trial

Presenter: Deya Alkhatib

March 06, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.